MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 413191 | Name: Cloxyquin
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cloxyquin has antitubercular activity.

Chemical Structure

Cloxyquin
Cloxyquin
CAS#130-16-5

Theoretical Analysis

MedKoo Cat#: 413191

Name: Cloxyquin

CAS#: 130-16-5

Chemical Formula: C9H6ClNO

Exact Mass: 179.0138

Molecular Weight: 179.60

Elemental Analysis: C, 60.19; H, 3.37; Cl, 19.74; N, 7.80; O, 8.91

Price and Availability

Size Price Availability Quantity
5g USD 250.00 2 Weeks
25g USD 550.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Cloxyquin; NSC35083; NSC-35083; NSC 35083; Cloxiquine; cloxyquin
IUPAC/Chemical Name
8-Quinolinol, 5-chloro-
InChi Key
CTQMJYWDVABFRZ-UHFFFAOYSA-N
InChi Code
InChI=1S/C9H6ClNO/c10-7-3-4-8(12)9-6(7)2-1-5-11-9/h1-5,12H
SMILES Code
OC1=C2N=CC=CC2=C(Cl)C=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 179.60 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Phopin K, Ruankham W, Prachayasittikul S, Prachayasittikul V, Tantimongcolwat T. Insight into the Molecular Interaction of Cloxyquin (5-chloro-8-hydroxyquinoline) with Bovine Serum Albumin: Biophysical Analysis and Computational Simulation. Int J Mol Sci. 2019 Dec 30;21(1):249. doi: 10.3390/ijms21010249. PMID: 31905871; PMCID: PMC6981711. 2: Zhang J, Nadtochiy SM, Urciuoli WR, Brookes PS. The cardioprotective compound cloxyquin uncouples mitochondria and induces autophagy. Am J Physiol Heart Circ Physiol. 2016 Jan 1;310(1):H29-38. doi: 10.1152/ajpheart.00926.2014. Epub 2015 Oct 30. PMID: 26519034; PMCID: PMC4796459. 3: Lengyel M, Dobolyi A, Czirják G, Enyedi P. Selective and state-dependent activation of TRESK (K2P 18.1) background potassium channel by cloxyquin. Br J Pharmacol. 2017 Jul;174(13):2102-2113. doi: 10.1111/bph.13821. Epub 2017 May 18. PMID: 28419410; PMCID: PMC5466531. 4: Wright PD, Weir G, Cartland J, Tickle D, Kettleborough C, Cader MZ, Jerman J. Cloxyquin (5-chloroquinolin-8-ol) is an activator of the two-pore domain potassium channel TRESK. Biochem Biophys Res Commun. 2013 Nov 15;441(2):463-8. PMID: 24383077. 5: Lengyel M, Erdélyi F, Pergel E, Bálint-Polonka Á, Dobolyi A, Bozsaki P, Dux M, Király K, Hegedűs T, Czirják G, Mátyus P, Enyedi P. Chemically Modified Derivatives of the Activator Compound Cloxyquin Exert Inhibitory Effect on TRESK (K2P18.1) Background Potassium Channel. Mol Pharmacol. 2019 Jun;95(6):652-660. doi: 10.1124/mol.118.115626. Epub 2019 Apr 12. PMID: 30979812. 6: Pettingill P, Weir GA, Wei T, Wu Y, Flower G, Lalic T, Handel A, Duggal G, Chintawar S, Cheung J, Arunasalam K, Couper E, Haupt LM, Griffiths LR, Bassett A, Cowley SA, Cader MZ. A causal role for TRESK loss of function in migraine mechanisms. Brain. 2019 Dec 1;142(12):3852-3867. doi: 10.1093/brain/awz342. PMID: 31742594; PMCID: PMC6906598. 7: Wantke F, Götz M, Jarisch R. Contact dermatitis from cloxyquin. Contact Dermatitis. 1995 Feb;32(2):112-3. doi: 10.1111/j.1600-0536.1995.tb00762.x. PMID: 7758311. 8: Cherdtrakulkiat R, Worachartcheewan A, Tantimavanich S, Lawung R, Sinthupoom N, Prachayasittikul S, Ruchirawat S, Prachayasittikul V. Discovery of novel halogenated 8-hydroxyquinoline-based anti-MRSA agents: In vitro and QSAR studies. Drug Dev Res. 2020 Feb;81(1):127-135. doi: 10.1002/ddr.21611. Epub 2019 Oct 16. PMID: 31617606. 9: Hongmanee P, Rukseree K, Buabut B, Somsri B, Palittapongarnpim P. In vitro activities of cloxyquin (5-chloroquinolin-8-ol) against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2007 Mar;51(3):1105-6. doi: 10.1128/AAC.01310-06. Epub 2006 Dec 18. PMID: 17178795; PMCID: PMC1803129. 10: Cherdtrakulkiat R, Boonpangrak S, Sinthupoom N, Prachayasittikul S, Ruchirawat S, Prachayasittikul V. Derivatives (halogen, nitro and amino) of 8-hydroxyquinoline with highly potent antimicrobial and antioxidant activities. Biochem Biophys Rep. 2016 Mar 24;6:135-141. doi: 10.1016/j.bbrep.2016.03.014. PMID: 29214226; PMCID: PMC5689172.